BioSpace News Archive

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2022.

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update.

Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), today announced that the underwriters of its previously announced initial public offering (the “IPO”) have exercised in part their over-allotment option to purchase an additional 772,091 American Depositary Shares (the “ADS”) of the Company at the IPO price of $6.00 per ADS.

Checkpoint Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights.

Johnson & Johnson will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16th.

STRO-002, FolRα-Targeting Antibody-Drug Conjugate (ADC): STRO-002 is being studied in the clinic, in both the United States and Europe, for patients with ovarian and endometrial cancers.

The Medical College of Wisconsin has dedicated its Genomic Sciences and Precision Medicine Center as the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine in honor of the couple’s $10 million gift to support new research and for MCW faculty studying the potential the human genome has to treat a wide variety of diseases.

Inotiv, Inc. announced financial results for the three months and six months ended March 31, 2022.

Antengene Corporation Limited announces that the Chinese Society of Clinical Oncology, the most prominent medical society for oncology in China, has added multiple XPOVIO® regimens for the treatment of relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma to its 2022 Guidelines for the Diagnosis and Treatment of Hematologic Malignancies and 2022 Guidelines for the Diagnosis and Treatment of Lymphomas.

Neovasc Inc. reported financial results for the quarter ended March 31, 2022.